|
Teva Pharmaceutical Industries Limited
Consolidated Statements Of Changes In Shareholders' Equity
(U.S. dollars in thousands)
|
| |
Ordinary shares
 |
|
|
|
|
|
|
| |
Number of shares(in thousands)
|
Par value
|
Additional paid-in capital
|
Deferred compensation
|
Retained earnings
|
Accumulated other comprehensive loss
|
Cost of company shares held by subsidiaries
|
Total
|
| Balance at January 1, 1998 |
124,398 |
$ 29,426 |
$ 156,115 |
$ (3,979) |
$ 460,679 |
$ (10,843) |
$ (15,392) |
$ 616,006 |
| Changes during 1998: |
|
|
|
|
|
|
|
|
| Net income |
|
|
|
|
70,803 |
|
|
70,803 |
| Differences from translation of non-dollar currency financial statements of subsidiaries and associated companies |
|
|
|
|
|
(1,980) |
|
(1,980)
|
| Total comprehensive income |
|
|
|
|
|
|
|
68,823 |
| Amortization of deferred compensation related to stock option plans |
|
|
|
1,626 |
|
|
|
1,626 |
| Exercise of options allotted to employees |
156 |
2 |
1,732 |
|
|
|
|
1,734 |
| Dividends |
|
|
|
|
(19,336) |
|
|
(19,336) |
| Cost of acquisition of Company shares, net of proceeds from sale |
|
|
(322)
|
|
|
|
(3,728)
|
(4,050)
|
| Balance at December 31, 1998 |
124,554 |
29,428 |
157,525 |
(2,353) |
512,146 |
(12,823) |
(19,120) |
664,803 |
| Changes during 1999: |
|
|
|
|
|
|
|
|
| Net income |
|
|
|
|
116,779 |
|
|
116,779 |
| Differences from translation of non-dollar currency financial statements of subsidiaries and associated companies |
|
|
|
|
|
(16,395) |
|
(16,395)
|
| Total comprehensive income |
|
|
|
|
|
|
|
100,384 |
| Deferred compensation related to employee stock option plans |
|
|
3 |
(3) |
|
|
|
|
| Amortization of deferred compensation related to stock option plans |
|
|
|
948 |
|
|
|
948 |
| Exercise of options allotted to employees |
404 |
7 |
5,481 |
|
|
|
|
5,488 |
| Dividends |
|
|
|
|
(20,018) |
|
|
(20,018) |
| Exercise of warrants |
69 |
1 |
294 |
|
|
|
|
295 |
| Distribution of stock dividend |
|
1,522 |
(1,522) |
|
|
|
|
|
| Cost of acquisition of Company shares, net of proceeds from sale |
|
|
1,815
|
|
|
|
(6,489)
|
(4,674)
|
| Balance at December 31, 1999 |
125,027 |
30,958 |
163,596 |
(1,408) |
608,907 |
(29,218) |
(25,609) |
747,226 |
| Changes during 2000: |
|
|
|
|
|
|
|
|
| Net income |
|
|
|
|
148,417 |
|
|
148,417 |
| Differences from translation of non-dollar currency financial statements of subsidiaries and associated companies |
|
|
|
|
|
(22,560) |
|
(22,560) |
| Unrealized holding losses on available-for-sale securities,net |
|
|
|
|
|
(774) |
|
(774)
|
| Total comprehensive income |
|
|
|
|
|
|
|
125,083 |
| Deferred compensation related to employee stock option plans |
|
|
56 |
(56) |
|
|
|
|
| Amortization of deferred compensation related to stock option plans |
|
|
|
785 |
|
|
|
785 |
| Exercise of options allotted to employees |
673 |
16 |
9,304 |
|
|
|
|
9,320 |
| Dividends |
|
|
|
|
(28,985) |
|
|
(28,985) |
| Exercise of warrants |
139 |
3 |
591 |
|
|
|
|
594 |
| Shares issued in connection with the acquisition of Novopharm (note 2a(1)) |
2,078 |
53 |
73,559 |
|
|
|
|
73,612 |
| Special shares that are exchangeable into 6,322 thousand ordinary shares issued in connection with the acquisition of Novopharm (note 2a(1)) |
|
|
226,388 |
|
|
|
|
226,388 |
| Cost of acquisition of Company shares, net of proceeds from sale |
|
|
2,698
|
|
|
|
(5,375)
|
(2,677)
|
| Balance at December 31, 2000 |
127,917
|
$ 31,030
|
$ 476,192
|
$ (679)
|
$ 728,339
|
$ (52,552)
|
$ (30,984)
|
$ 1,151,346
|
The accompanying notes are an integral part of
the financial statements.
|
